External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul><li><span data-sheets-value='{"1":2,"2":"Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below."}' data-sheets-userformat='{"2":33281,"3":{"1":0},"12":0,"18":1}'>Over the weekend, in a 16-0 vote, the FDA’s Oncologic Drug Advisory Committee (ODAC) decided Y-mAbs therapeutics’ omburtamab (commercialized as OMBLASTYS®) had not provided sufficient evidence to conclude improvement in overall survival for the treatment of central nervous system (CNS)/leptomeningeal metastasis from paediatric neuroblastoma. </li><li><span data-sheets-value='{"1":2,"2":"Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below."}' data-sheets-userformat='{"2":33281,"3":{"1":0},"12":0,"18":1}'>The PDUFA date had been set for November 30 2022, following BLA submission in April this year. </li><li><span data-sheets-value='{"1":2,"2":"Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below."}' data-sheets-userformat='{"2":33281,"3":{"1":0},"12":0,"18":1}'>Omburtamab represented the potential expansion of Y-mAb’s neuroblastoma treatment offering following FDA approval of their DANYELZATM drug in 2020. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Over the weekend, in a 16-0 vote, the FDA’s Oncologic Drug Advisory Committee (ODAC) decided Y-mAbs therapeutics’ omburtamab (commercialized as OMBLASTYS®) had not provided sufficient evidence to conclude improvement in overall survival for the treatment of central nervous system (CNS)/leptomeningeal metastasis from paediatric neuroblastoma. The PDUFA date had been set for November 30 2022, following BLA submission in April this year. Omburtamab represented the potential expansion of Y-mAb’s neuroblastoma treatment offering following FDA approval of their DANYELZATM drug in 2020. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - FDA No-Go for Y-MAb’s Neuroblastoma Drug